Quest Diagnostics Incorporated Stock Today
| DGX Stock | USD 163.89 2.57 1.59% |
Performance5 of 100
| Odds Of DistressLess than 9
|
Quest Diagnostics is trading at 163.89 as of the 21st of November 2024; that is 1.59 percent increase since the beginning of the trading day. The stock's open price was 161.32. Quest Diagnostics has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat modest performance during the last 90 days. Note, on May 4, 2024, Representative Earl Blumenauer of US Congress acquired under $15k worth of Quest Diagnostics's common stock.
Business Domain Health Care Equipment & Services | IPO Date 17th of December 1996 | Category Healthcare | Classification Health Care |
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey. Quest Diagnostics operates under Diagnostics Research classification in the United States and is traded on New York Stock Exchange. The company has 111.61 M outstanding shares of which 2.38 M shares are currently shorted by investors with about 3.02 days to cover. More on Quest Diagnostics Incorporated
Moving together with Quest Stock
Moving against Quest Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Quest Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Stephen Rusckowski | ||||
| Thematic Idea | Healthcare (View all Themes) | ||||
| Old Name | Diploma Group Limited | ||||
| Business Concentration | Health Care Providers & Services, Health Care Equipment & Services, Health Care, NYSE Composite, SP 500 Index, Healthcare, Health Care, Health Care Providers & Services, Diagnostics & Research, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsQuest Diagnostics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Quest Diagnostics' financial leverage. It provides some insight into what part of Quest Diagnostics' total assets is financed by creditors.
| |||||
Quest Diagnostics Incorporated (DGX) is traded on New York Stock Exchange in USA. It is located in 500 Plaza Drive, Secaucus, NJ, United States, 07094 and employs 50,000 people. Quest Diagnostics is listed under Health Care Providers & Services category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a total capitalization of 18.01 B. Quest Diagnostics runs under Health Care Providers & Services sector within Health Care industry. The entity has 111.61 M outstanding shares of which 2.38 M shares are currently shorted by investors with about 3.02 days to cover.
Quest Diagnostics Incorporated has about 315 M in cash with 1.27 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.15.
Check Quest Diagnostics Probability Of Bankruptcy
Ownership AllocationQuest Diagnostics owns a total of 111.61 Million outstanding shares. The majority of Quest Diagnostics Incorporated outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Quest Diagnostics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Quest Diagnostics. Please pay attention to any change in the institutional holdings of Quest Diagnostics as this could imply that something significant has changed or is about to change at the company. Please note that on May 4, 2024, Representative Earl Blumenauer of US Congress acquired under $15k worth of Quest Diagnostics's common stock.
Check Quest Ownership Details
Quest Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Amvescap Plc. | 2024-06-30 | 1.8 M | |
| Goldman Sachs Group Inc | 2024-06-30 | 1.7 M | |
| Jpmorgan Chase & Co | 2024-06-30 | 1.5 M | |
| Wells Fargo & Co | 2024-06-30 | 1.5 M | |
| Fiduciary Management, Inc. Of Milwaukee | 2024-06-30 | 1.4 M | |
| Norges Bank | 2024-06-30 | 1.3 M | |
| Citadel Advisors Llc | 2024-06-30 | 1.2 M | |
| Fmr Inc | 2024-09-30 | 1.1 M | |
| Northern Trust Corp | 2024-09-30 | 1 M | |
| Vanguard Group Inc | 2024-09-30 | 14 M | |
| Blackrock Inc | 2024-06-30 | 10.1 M |
Quest Diagnostics Historical Income Statement
Quest Stock Against Markets
Quest Diagnostics Corporate Directors
| Gail Wilensky | Independent Director | Profile | |
| Wright Lassiter | Independent Director | Profile | |
| Gary Pfeiffer | Independent Director | Profile | |
| Vicky Gregg | Independent Director | Profile |
Additional Tools for Quest Stock Analysis
When running Quest Diagnostics' price analysis, check to measure Quest Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quest Diagnostics is operating at the current time. Most of Quest Diagnostics' value examination focuses on studying past and present price action to predict the probability of Quest Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quest Diagnostics' price. Additionally, you may evaluate how the addition of Quest Diagnostics to your portfolios can decrease your overall portfolio volatility.